This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Reading back through the four-week escalation interval threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Worth separating two things that post #31 runs together.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
That is one dataset and I would not build a rule on it.
The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you are assessing a stable concentration rather than a rising one.
I would be interested in a counterexample if anyone has one.
I would put moderate confidence on the mainstream reading of four-week escalation interval and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Picking up post #35: that is the part I would want checked first.
There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".
Answering the question post #35 raises rather than the one it answers.
Two people in this thread mean different things by four-week escalation interval and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.
I would put the burden of proof on the interesting explanation, not the dull one.
Post #40 is the version of this I will quote in future. One addition.
The version of four-week escalation interval that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you are assessing a stable concentration rather than a rising one.
Anyone with a larger sample, please post it.
Building on post #43 rather than restating it.
Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.
I keep a log of this specifically because memory is unreliable about it.
Post #42 put the caveat in the right place and I want to underline it.
Agreed on four-week escalation interval, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
Taking four-week escalation interval seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
The right answer here may simply be that it has not been measured.
Four-week escalation interval is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
When a dose reduction is the correct response to a side effect — a second dataset
When a dose reduction is the correct response to a side effect — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on dose…
|
+10 | 14 | 42k | 2mo |
|
The lowest dose that does anything: is that a real question?
Asking directly, because I could not find a straight answer: The lowest dose that does anything: is that a real question? I have read the maintained page on this and I still have a gap, so I am asking rather…
|
+100 | 111 | 9.1k | 5mo |
|
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about four-week escalation…
|
+131 | 147 | 47k | 18mo |
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. Asking about steady state directly, because I have read four…
|
+127 | 137 | 32k | 8mo |
|
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. A narrow question about Dose numbers across compounds, deliberately narrow, because…
|
+14 | 18 | 1.2k | 13mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Why the titration planner refuses to produce a schedule below a floor
The question in the title: Why the titration planner refuses to produce a schedule below a floor I will give what I have already checked below so nobody repeats it. A follow-up question about titration…
|
+120 | 146 | 14k | 10mo |
|
A partial dose because the pen emptied mid-injection
A partial dose because the pen emptied mid-injection Writing it up because I had to work it out twice and would rather nobody else did. A methods question rather than a substantive one, about partial dose…
|
+108 | 120 | 1.5k | 7mo |
|
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
|
+35 | 39 | 547 | 11mo |
|
[2026 update] How much of the diluent volume the powder itself displaces
The question in the title: How much of the diluent volume the powder itself displaces I will give what I have already checked below so nobody repeats it. Writing this out with the numbers in it, because…
|
+89 | 100 | 3.2k | 8mo |
|
Micro-titration: a disputed topic, argued properly
Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on…
|
+99 | 110 | 61k | 2d |